RU2020107732A - Схема дозирования модулятора s1p с немедленным высвобождением - Google Patents

Схема дозирования модулятора s1p с немедленным высвобождением Download PDF

Info

Publication number: RU2020107732A
Authority: RU; Russia
Prior art keywords: per day; siponimod; patient; treatment; dosage form
Prior art date: 2014-04-10

Application number

RU2020107732A

Other languages

English (en)

Russian (ru)

Inventor

Эрик ЛЕГАНЬНЕ

Эрик Валлстрём

Филипп Мишель Рене БУЙО

Эмерик Рейно

Франк ДАЛЬКЕ

Original Assignee

Новартис Аг

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-10

Filing date

2015-04-08

Publication date

2020-03-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52988364&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2020107732(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-04-08 Application filed by Новартис Аг filed Critical Новартис Аг

2020-03-30 Publication of RU2020107732A publication Critical patent/RU2020107732A/ru

Links

239000012729 immediate-release (IR) formulation Substances 0.000 title claims 20
KIHYPELVXPAIDH-HNSNBQBZSA-N 1-[[4-[(e)-n-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-c-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid Chemical compound CCC1=CC(C(\C)=N\OCC=2C=C(C(C3CCCCC3)=CC=2)C(F)(F)F)=CC=C1CN1CC(C(O)=O)C1 KIHYPELVXPAIDH-HNSNBQBZSA-N 0.000 claims 31
229950005693 siponimod Drugs 0.000 claims 31
239000002552 dosage form Substances 0.000 claims 27
208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 16
201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 16
238000004448 titration Methods 0.000 claims 14
238000012423 maintenance Methods 0.000 claims 11
230000001363 autoimmune Effects 0.000 claims 6
238000000034 method Methods 0.000 claims 6
238000001727 in vivo Methods 0.000 claims 5
230000002057 chronotropic effect Effects 0.000 claims 3
239000003814 drug Substances 0.000 claims 3
230000000694 effects Effects 0.000 claims 3
238000000338 in vitro Methods 0.000 claims 3
230000003902 lesion Effects 0.000 claims 3
239000008363 phosphate buffer Substances 0.000 claims 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 3
229920000053 polysorbate 80 Polymers 0.000 claims 3
VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 claims 2
208000023275 Autoimmune disease Diseases 0.000 claims 2
230000006735 deficit Effects 0.000 claims 2
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
239000004359 castor oil Substances 0.000 claims 1
235000019438 castor oil Nutrition 0.000 claims 1
230000006866 deterioration Effects 0.000 claims 1
239000007884 disintegrant Substances 0.000 claims 1
229940079593 drug Drugs 0.000 claims 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
229940049654 glyceryl behenate Drugs 0.000 claims 1
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims 1
229940046813 glyceryl palmitostearate Drugs 0.000 claims 1
239000008172 hydrogenated vegetable oil Substances 0.000 claims 1
230000001771 impaired effect Effects 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
239000011814 protection agent Substances 0.000 claims 1
229940114926 stearate Drugs 0.000 claims 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

RU2020107732A 2014-04-10 2015-04-08 Схема дозирования модулятора s1p с немедленным высвобождением RU2020107732A (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201461977816P	2014-04-10	2014-04-10
US61/977,816		2014-04-10

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2016143979A Division RU2715734C2 (ru)	2014-04-10	2015-04-08	Схема дозирования модулятора s1p с немедленным высвобождением

Publications (1)

Publication Number	Publication Date
RU2020107732A true RU2020107732A (ru)	2020-03-30

Family

ID=52988364

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
RU2020107732A RU2020107732A (ru)	2014-04-10	2015-04-08	Схема дозирования модулятора s1p с немедленным высвобождением
RU2016143979A RU2715734C2 (ru)	2014-04-10	2015-04-08	Схема дозирования модулятора s1p с немедленным высвобождением

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
RU2016143979A RU2715734C2 (ru)	2014-04-10	2015-04-08	Схема дозирования модулятора s1p с немедленным высвобождением

Country Status (16)

Country	Link
US (3)	US20170027907A1 (ko)
EP (3)	EP4074312A1 (ko)
JP (1)	JP6674903B2 (ko)
KR (2)	KR20160141841A (ko)
CN (2)	CN116650467A (ko)
AU (2)	AU2015246036A1 (ko)
CA (1)	CA2943598C (ko)
CL (1)	CL2016002562A1 (ko)
IL (2)	IL305337A (ko)
MX (1)	MX2016013245A (ko)
PH (1)	PH12016501965A1 (ko)
RU (2)	RU2020107732A (ko)
SG (1)	SG11201607894RA (ko)
TW (1)	TW201622721A (ko)
WO (1)	WO2015155709A1 (ko)
ZA (1)	ZA201606519B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20170027907A1 (en) *	2014-04-10	2017-02-02	Eric Legangneux	Sip modulator immediate release dosage regimen
US11629124B2 (en)	2017-03-09	2023-04-18	Novartis Ag	Solid forms comprising an oxime ether compound, compositions and methods of use thereof
JP2020535147A (ja) *	2017-09-29	2020-12-03	ノバルティスアーゲー	シポニモドの投与レジメン
WO2019064217A1 (en) *	2017-09-29	2019-04-04	Novartis Ag	DOSAGE DIAGRAM OF SIPONIMOD
US20210369732A1 (en) *	2018-03-01	2021-12-02	Astrazeneca Ab	PHARMACEUTICAL COMPOSITIONS COMPRISING (2S)-N-{(1S)-1-CYANO-2-[4-(3-METHYL-2-OXO-2,3-DIHYDRO-1,3-BENZOXAZOL-5-yl)PHENYL]ETHYL}-1,4-OXAZEPANE-2-CARBOXAMIDE
KR20210032431A (ko)	2018-07-17	2021-03-24	인스메드 인코포레이티드	루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
CN109908095A (zh) *	2019-04-08	2019-06-21	肇庆学院	一种西尼莫德片剂及制备方法
AU2020372647A1 (en)	2019-10-31	2022-06-16	Idorsia Pharmaceuticals Ltd	Combination of a CXCR7 antagonist with an S1P1 receptor modulator
US11135197B2 (en)	2020-02-07	2021-10-05	Argentum Pharmaceuticals Llc	Dosage regimen of an S1P receptor modulator

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS53041B (en) *	2008-12-18	2014-04-30	Novartis Ag	1- [4- [1- (4-CYCLOHEXYL-3-TRIFLUOROMETHYL-BENZYLOXYIMINO) -ETHYL] -2-ETHYL-BENZYL] -AZETIDINE-3-CARBOXYLIC ACID
PL3409274T3 (pl) *	2008-12-22	2020-06-01	Novartis Ag	Schemat dawkowania dla agonisty receptora s1p
JO3044B1 (ar) *	2008-12-22	2016-09-05	Novartis Ag	نظام تناول جرعة لمنبه مستقبل s1p
EP2482810A2 (en) *	2009-09-29	2012-08-08	Novartis AG	Dosage regimen of an s1p receptor modulator
LT2661261T (lt) *	2011-01-07	2019-10-25	Novartis Ag	Imunosupresantų kompozicijos
WO2012095853A1 (en)	2011-01-10	2012-07-19	Novartis Pharma Ag	Modified release formulations comprising sip receptor modulators
JP2014530835A (ja) *	2011-10-21	2014-11-20	ノバルティスアーゲー	Ｓ１ｐ受容体モジュレーターまたはｓ１ｐ受容体アゴニストのための投薬量レジメン
US20170027907A1 (en) *	2014-04-10	2017-02-02	Eric Legangneux	Sip modulator immediate release dosage regimen

2015
- 2015-04-08 US US15/300,989 patent/US20170027907A1/en not_active Abandoned
- 2015-04-08 WO PCT/IB2015/052550 patent/WO2015155709A1/en active Application Filing
- 2015-04-08 IL IL305337A patent/IL305337A/en unknown
- 2015-04-08 AU AU2015246036A patent/AU2015246036A1/en not_active Abandoned
- 2015-04-08 TW TW104111330A patent/TW201622721A/zh unknown
- 2015-04-08 EP EP21212400.2A patent/EP4074312A1/en active Pending
- 2015-04-08 CN CN202310667400.7A patent/CN116650467A/zh active Pending
- 2015-04-08 RU RU2020107732A patent/RU2020107732A/ru unknown
- 2015-04-08 CA CA2943598A patent/CA2943598C/en active Active
- 2015-04-08 CN CN201580031360.0A patent/CN106456552A/zh active Pending
- 2015-04-08 SG SG11201607894RA patent/SG11201607894RA/en unknown
- 2015-04-08 EP EP15717256.0A patent/EP3129020A1/en not_active Withdrawn
- 2015-04-08 RU RU2016143979A patent/RU2715734C2/ru not_active Application Discontinuation
- 2015-04-08 KR KR1020167031062A patent/KR20160141841A/ko active Application Filing
- 2015-04-08 KR KR1020227039781A patent/KR20220156981A/ko not_active Application Discontinuation
- 2015-04-08 EP EP20215763.2A patent/EP3831378A1/en not_active Withdrawn
- 2015-04-08 MX MX2016013245A patent/MX2016013245A/es unknown
- 2015-04-08 JP JP2016561731A patent/JP6674903B2/ja active Active
2016
- 2016-09-21 ZA ZA2016/06519A patent/ZA201606519B/en unknown
- 2016-09-22 IL IL247986A patent/IL247986A0/en unknown
- 2016-10-04 PH PH12016501965A patent/PH12016501965A1/en unknown
- 2016-10-07 CL CL2016002562A patent/CL2016002562A1/es unknown
2018
- 2018-08-21 US US16/106,072 patent/US20190054065A1/en not_active Abandoned
2020
- 2020-05-12 AU AU2020203107A patent/AU2020203107B2/en active Active
- 2020-06-02 US US16/890,722 patent/US20220016076A1/en active Pending

Also Published As

Publication number	Publication date
JP6674903B2 (ja)	2020-04-01
RU2715734C2 (ru)	2020-03-03
IL247986A0 (en)	2016-11-30
JP2017510607A (ja)	2017-04-13
EP3831378A1 (en)	2021-06-09
CN116650467A (zh)	2023-08-29
EP4074312A1 (en)	2022-10-19
MX2016013245A (es)	2017-01-16
US20170027907A1 (en)	2017-02-02
KR20220156981A (ko)	2022-11-28
AU2015246036A1 (en)	2016-10-13
IL305337A (en)	2023-10-01
CA2943598A1 (en)	2015-10-15
RU2016143979A (ru)	2018-05-14
CN106456552A (zh)	2017-02-22
CA2943598C (en)	2023-03-07
ZA201606519B (en)	2017-11-29
AU2020203107B2 (en)	2021-10-21
US20220016076A1 (en)	2022-01-20
RU2016143979A3 (ko)	2018-11-12
KR20160141841A (ko)	2016-12-09
SG11201607894RA (en)	2016-10-28
CL2016002562A1 (es)	2017-07-28
PH12016501965A1 (en)	2017-01-09
AU2020203107A1 (en)	2020-05-28
EP3129020A1 (en)	2017-02-15
US20190054065A1 (en)	2019-02-21
WO2015155709A1 (en)	2015-10-15
TW201622721A (zh)	2016-07-01

Publication	Publication Date	Title
RU2020107732A (ru)	2020-03-30	Схема дозирования модулятора s1p с немедленным высвобождением
WO2016062283A1 (zh)	2016-04-28	抗发炎用药物在制备抑制癌症的医药组合物中的应用
JP2017510607A5 (ko)	2018-05-17
JP6446552B2 (ja)	2018-12-26	体重と体脂肪減少に用いられる組成物およびその医薬品と使用
PH12015502691A1 (en)	2016-03-14	Use of high dose pridopidine for treating huntington's disease
RU2011138490A (ru)	2013-04-20	Фармацевтические композиции с мгновенным высвобождением, содержащие оксикодон и налоксон
RU2008119454A (ru)	2009-11-27	Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
RU2013127420A (ru)	2015-01-10	Способы уменьшения психогенного или компульсивного переедания
RU2012128109A (ru)	2014-02-20	Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты)
JP2016505050A5 (ko)	2017-02-23
FI3352735T3 (fi)	2023-10-20	Pitkitetysti vapauttavia olantsapiiniformulaatioita
Burns et al.	2014	A cautionary tale of oral naloxone
US20190224208A1 (en)	2019-07-25	Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
MX2023001014A (es)	2023-03-01	Composiciones farmaceuticas que comprenden venglustat.
Senanarong et al.	2011	Safety and tolerability of galantamine in possible Alzheimer’s disease with or without cerebrovascular disease and vascular dementia in Thai patients
RU2468813C1 (ru)	2012-12-10	Средство для профилактики или лечения острых и хронических нарушений мозгового кровообращения, применение и способ лечения
Ayd et al.	2019	Severe urinary retention in a young female patient using duloxetine: a case report
Venter et al.	2021	Sickle Cell Pain Crisis Complicated by Opioid Induced Hyperalgesia, Treated with Low Dose Ketamine Infusion
RU2015128914A (ru)	2017-02-14	Составы лоразепама с контролируемым высвобождением
MX2022002038A (es)	2022-03-11	Composicion farmaceutica para el tratamiento del insomnio.
Safety	2010	Higher-Dose Alzheimer’s Drug Gets FDA Approval
RU2015147233A (ru)	2017-05-15	Способы лечения, включающие эсликарбазепин или эсликарбазепина ацетат
CN113015524A (zh)	2021-06-22	氨基甲酸酯化合物和包含其的制剂在预防、缓解或治疗急性应激障碍或创伤后应激障碍中的用途
CN110075302A (zh)	2019-08-02	一种治疗抑郁和失眠的组合物及其用途
EA028400B1 (ru)	2017-11-30	Способ профилактики и лечения ожирения и избыточного веса и связанных с ними нарушений